The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
Eric McDade(University of Pittsburgh), Stefan F. Lichtenthaler(German Center for Neurodegenerative Diseases), Iryna Voytyuk(VIB-KU Leuven Center for Brain & Disease Research), Bart De Strooper(VIB-KU Leuven Center for Brain & Disease Research), Randall J. Bateman(Washington University in St. Louis), María C. Carrillo(Brigham and Women's Hospital), Robert Vassar(Northwestern University), Riqiang Yan(UConn Health), Colin L. Masters(Mental Health Research Institute), Eric M. Reiman(Alzheimer's Association), Christian Haass(German Center for Neurodegenerative Diseases), Reisa A. Sperling(Harvard University), Paul Aisen(University of Southern California), Pierre N. Tariot(Banner Health)
Cited by 136
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k